aGF Platform

About Scarcell Therapeutics

Scarcell Therapeutics is a clinical-stage biotech developing an allogenic gingival fibroblast (aGF) platform for regenerative medicine, initially targeting osteoarthritis. Its lead candidate, aGF, is a single-injection therapy with demonstrated safety and efficacy in over 800 companion animals and is preparing for Phase Ib human trials in Europe in mid-2025. The company's technology leverages the immune-tolerant properties of gingival fibroblasts to enable long-lasting effects without immunosuppression, positioning it as a potential disease-modifying therapy in a large, underserved market.

About Scarcell Therapeutics

Scarcell Therapeutics is a clinical-stage biotech developing an allogenic gingival fibroblast (aGF) platform for regenerative medicine, initially targeting osteoarthritis. Its lead candidate, aGF, is a single-injection therapy with demonstrated safety and efficacy in over 800 companion animals and is preparing for Phase Ib human trials in Europe in mid-2025. The company's technology leverages the immune-tolerant properties of gingival fibroblasts to enable long-lasting effects without immunosuppression, positioning it as a potential disease-modifying therapy in a large, underserved market.

Therapeutic Areas